IP Library Granted Patent US 9,156,884
Granted Patent B2
US 9,156,884 · App. 14/176,930 · Granted Oct 13, 2015

Inhibitors of beta integrin-G protein alpha subunit binding interactions

Inventor: Xiaoping Du (Willowbrook, IL)
Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
C07K7/06C07K14/4722C07K14/70546C07K14/70557A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,156,884
App. No.
14/176,930
Granted
Oct 13, 2015
Kind
B2
Abstract

Provided herein are compounds that inhibit a binding interaction between a β integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Claims (30)

1. A method of inhibiting thrombosis in a subject in need thereof comprising administering to the subject a peptide, or a conjugate or a micelle comprising the peptide, in an amount effective to inhibit thrombosis, wherein the peptide comprises an amino acid sequence

Phe Xaa 1 Xaa 2 Glu Xaa 3 Xaa 4

wherein Xaa 1 is Glu or Gln and Xaa 2 is Glu, Lys, Ser, or Ala,

wherein Xaa 3 is Lys, Arg, or Gln and Xaa 4 Met, Leu, Ala, Ser, or Gln,

wherein the peptide is a 6-mer, 7-mer, 8-mer, 9-mer-10-mer, 11-mer, 12-mer, 13-mer, or 14-mer.

2. A method of treating a stroke or a heart attack in a subject in need thereof comprising administering to the subject a peptide, or a conjugate or micelle comprising the peptide, in an amount effective to treat stroke or heart attack, wherein the peptide comprises an amino acid sequence

Phe Xaa 1 , Xaa 2 Glu Xaa 3 Xaa 4

wherein Xaa 1 , is Glu or Gln and Xaa 2 is Glu, Lys, Ser, or Ala,

wherein Xaa 3 is Lys, Arg, or Gln and Xaa 4 Met, Leu, Ala, Ser, or Gln,

wherein the peptide is a 6-mer, 7-mer, 8-mer, 9-mer-10-mer, 11-mer, 12-mer, 13-mer, or 14-mer.

3. A method of inhibiting formation of a blood clot inside a blood vessel in a subject in need thereof comprising administering to the subject a peptide, or a conjugate or a micelle comprising the peptide, in an amount effective to inhibit the formation of a blood clot inside a blood vessel, wherein the peptide comprises the amino acid sequence FEEER (SEQ ID NO: 84), wherein the peptide is about 5 to about 14 amino acids in length, and optionally, covalently attached to a fatty acid.

4. A method of treating a stroke or a heart attack in a subject in need thereof comprising administering to the subject a peptide, or a conjugate or micelle comprising the peptide, in an amount effective to treat stroke or heart attack, wherein the peptide comprises the amino acid sequence FEEER (SEQ ID NO: 84), wherein the peptide is about 5 to about 14 amino acids in length, and optionally, covalently attached to a fatty acid.

5. The method of claim 1 , wherein (i) Xaa 1 is Glu and Xaa 2 is Glu, Lys, or Ala or (ii) Xaa 1 is Gln and Xaa 2 is Ser.

6. The method of claim 5 , wherein each of Xaa 1 and Xaa 2 is Glu.

7. The method of claim 6 , wherein Xaa 3 is Arg and Xaa 4 is Ala.

8. The method of claim 7 , wherein the peptide comprises, consists essentially of, or consists of FEEERA (SEQ ID NO: 87).

9. The method of claim 1 , wherein the peptide comprises a fatty acid, optionally, a C4-C30 fatty acid.

10. The method of claim 9 , wherein the fatty acid is covalently attached to the N-terminus of the peptide.

11. The method of claim 10 , wherein the peptide comprises, consists essentially of, or consists of FEEERA (SEQ ID NO: 87), wherein the Phe at position 1 is covalently attached to a fatty acid, optionally, a C4-C30 fatty acid.

12. The method of claim 2 , wherein (i) Xaa 1 is Glu and Xaa 2 is Glu, Lys, or Ala or (ii) Xaa 1 is Gln and Xaa 2 is Ser.

13. The method of claim 12 , wherein each of Xaa 1 and Xaa 2 is Glu.

14. The method of claim 13 , wherein Xaa 3 is Arg and Xaa 4 is Ala.

15. The method of claim 14 , wherein the peptide comprises, consists essentially of, or consists of FEEERA (SEQ ID NO: 87).

16. The method of claim 2 , wherein the peptide comprises a fatty acid, optionally, a C4-C30 fatty acid.

17. The method of claim 16 , wherein the fatty acid is covalently attached to the N-terminus of the peptide or peptide analog.

18. The method of claim 17 , wherein the peptide comprises, consists essentially of, or consists of FEEERA (SEQ ID NO: 87), wherein the Phe at position 1 is covalently attached to a fatty acid, optionally, a C4-C30 fatty acid.

19. The method of claim 3 , wherein the peptide is a 5-mer, 6-mer, 7-mer, 8-mer, or 9-mer.

20. The method of claim 4 , wherein the peptide is a 5-mer, 6-mer, 7-mer, 8-mer, or 9-mer.

21. The method of claim 3 , wherein the fatty acid is covalently attached to the N-terminal amino acid of the peptide.

22. The method of claim 4 , wherein the fatty acid is covalently attached to the N-terminal amino acid of the peptide.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 16, 2018
From: UNIVERSITY OF ILLINOIS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046554/0341 →
Continuity (5)
Continuation 13621064
Continuation In Part PCTUS2011028567 · Mar 15, 2011
Provisional Application 61314027 · Mar 15, 2010
Provisional Application 61433037 · Jan 14, 2011
Related Publication 20140228295A1 · Aug 14, 2014